Every material Form 8-K Inhibikase Therapeutics, Inc. has filed with the SEC since August 26, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Inhibikase Therapeutics appointed Scott Wasserman, MD, as a Class III director effective October 19, 2026, and Dennis Berman resigned from the board the same day. The change involves board and committee seats rather than operations, and the company said Berman's resignation was not due to any disagreement with management.
Scott Wasserman, MD, currently Chief Medical Officer of Kailera Therapeutics, joins the board effective October 19, 2026, and will serve on the Compensation Committee.
Wasserman receives an initial new director grant of non-qualified stock options to purchase up to 310,000 shares of common stock.
Dennis Berman resigned from the board effective October 19, 2026, including his roles as Compensation Committee chair and Audit Committee member.
The company's board has determined Wasserman is independent under Nasdaq listing standards and SEC rules.
Inhibikase Therapeutics furnished an updated corporate presentation dated September 2026 for use in meetings with investors and analysts. The filing is a Regulation FD disclosure with no new financial results, guidance, or transaction terms; the presentation restates the company's IKT-001 Phase 3 IMPROVE-PAH development plan and timelines.
Updated corporate presentation dated September 2026 furnished as Exhibit 99.1, issued September 8, 2026
Presentation describes single pivotal Phase 3 IMPROVE-PAH study enrolling across 26 countries and 46 active sites, with a target of about 180 planned sites
Projected timelines include interim safety readout in 1H 2027, unblinded PVR readout in mid 2028, and topline 6MWD readout in mid 2029
Filing states cash runway through Phase 3 Part B topline data readout, assuming full and timely exercise of Series A and B Warrants
Inhibikase Therapeutics, Inc. dismissed CohnReznick LLP as its independent registered public accounting firm effective immediately and appointed Deloitte & Touche LLP for fiscal 2026, both approved by the Audit Committee on August 21, 2026. The prior auditor's reports on the 2025 and 2024 financial statements contained no adverse opinion, disclaimer, or qualification, and the filing reports no disagreements with the former auditor. The filing also discloses one reportable event: a material weakness in internal control over financial reporting that CohnReznick flagged for fiscal 2024, which the company says was remediated by prior management.
CohnReznick LLP dismissed effective immediately; Audit Committee approved the change on August 21, 2026
Deloitte & Touche LLP appointed as independent auditor for the fiscal year ending December 31, 2026
CohnReznick reported a material weakness in internal control over financial reporting during fiscal 2024, disclosed in the 10-Q for the quarter ended June 30, 2024
CohnReznick's response letter, dated August 26, 2026, is filed as Exhibit 16.1
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Inhibikase Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →